Immix Biopharma Inc
IMMX5.810USD
+0.090+1.57%
收盤 12/22, 16:00（美東）報價延遲15分鐘
191.94M總市值
虧損本益比TTM
關於 Immix Biopharma Inc 公司
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Immix Biopharma Inc簡介
公司代碼IMMX
公司名稱Immix Biopharma Inc
上市日期Dec 16, 2021
CEORachman (Ilya)
員工數量18
證券類型Ordinary Share
年結日Dec 16
公司地址11400 West Olympic Blvd.
城市LOS ANGELES
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編90064
電話18889581084
網址https://immixbio.com/
公司代碼IMMX
上市日期Dec 16, 2021
CEORachman (Ilya)
Immix Biopharma Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.86M
--
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
421.94K
--
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
174.75K
-0.13%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
173.19K
+161.79%
Mr. Gabriel Morris
Mr. Gabriel Morris
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Graham Ross
Dr. Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Acting Chief Medical Officer, Head - Clinical Development
--
--
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Dr. Ilya Rachman, M.D., Ph.D.
Dr. Ilya Rachman, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Carey Ng, Ph.D.
Mr. Carey Ng, Ph.D.
Independent Director
Independent Director
--
--
Dr. Vladimir Torchilin, Ph.D.
Dr. Vladimir Torchilin, Ph.D.
Scientific Co-Founder
Scientific Co-Founder
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.86M
--
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
421.94K
--
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
174.75K
-0.13%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
173.19K
+161.79%
Mr. Gabriel Morris
Mr. Gabriel Morris
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Graham Ross
Dr. Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Acting Chief Medical Officer, Head - Clinical Development
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Hsu (Jason)
9.32%
GKCC, LLC
6.21%
Rachman (Ilya M)
2.19%
Ng (Carey)
2.00%
Bleichroeder LP
1.63%
其他
78.65%
持股股東
持股股東
佔比
Hsu (Jason)
9.32%
GKCC, LLC
6.21%
Rachman (Ilya M)
2.19%
Ng (Carey)
2.00%
Bleichroeder LP
1.63%
其他
78.65%
股東類型
持股股東
佔比
Individual Investor
16.15%
Corporation
6.21%
Investment Advisor
4.09%
Investment Advisor/Hedge Fund
1.78%
Hedge Fund
0.21%
Venture Capital
0.07%
Research Firm
0.07%
其他
71.42%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
60
2.79M
8.55%
-1.92M
2025Q2
65
14.67M
52.67%
-1.12M
2025Q1
66
14.50M
53.34%
-1.02M
2024Q4
67
14.42M
52.43%
-1.29M
2024Q3
66
15.60M
56.77%
-243.92K
2024Q2
66
15.89M
59.32%
-308.72K
2024Q1
64
15.43M
77.52%
+5.90M
2023Q4
57
11.10M
62.12%
+3.00M
2023Q3
52
12.47M
73.23%
+2.63M
2023Q2
46
9.35M
66.71%
-203.85K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Hsu (Jason)
4.86M
14.87%
--
--
Apr 22, 2025
GKCC, LLC
3.24M
9.92%
--
--
Apr 22, 2025
Rachman (Ilya M)
1.14M
3.49%
+2.50K
+0.22%
Sep 17, 2025
Ng (Carey)
1.05M
3.2%
--
--
Apr 22, 2025
Bleichroeder LP
850.00K
2.6%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
698.54K
2.14%
--
--
Jun 30, 2025
Chang (Nancy T)
421.94K
1.29%
+421.94K
--
Sep 08, 2025
Morris (Gabriel S)
585.64K
1.79%
+2.60K
+0.45%
Sep 16, 2025
Lynwood Capital Management Inc.
405.00K
1.24%
+405.00K
--
Mar 31, 2024
Geode Capital Management, L.L.C.
161.12K
0.49%
+373.00
+0.23%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
佔比0.01%
Dimensional US Core Equity 1 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Immix Biopharma Inc的前五大股東是誰？
Immix Biopharma Inc的前五大股東如下：
Hsu (Jason)持有股份：4.86M佔總股份比例：14.87%。
GKCC, LLC持有股份：3.24M佔總股份比例：9.92%。
Rachman (Ilya M)持有股份：1.14M佔總股份比例：3.49%。
Ng (Carey)持有股份：1.05M佔總股份比例：3.20%。
Bleichroeder LP持有股份：850.00K佔總股份比例：2.60%。
Hsu (Jason)持有股份：4.86M佔總股份比例：14.87%。
GKCC, LLC持有股份：3.24M佔總股份比例：9.92%。
Rachman (Ilya M)持有股份：1.14M佔總股份比例：3.49%。
Ng (Carey)持有股份：1.05M佔總股份比例：3.20%。
Bleichroeder LP持有股份：850.00K佔總股份比例：2.60%。
Immix Biopharma Inc的前三大股東類型是什麼？
Immix Biopharma Inc 的前三大股東類型分別是：
Hsu (Jason)
GKCC, LLC
Rachman (Ilya M)
Hsu (Jason)
GKCC, LLC
Rachman (Ilya M)
有多少機構持有Immix Biopharma Inc(IMMX)的股份？
截至2025Q3，共有60家機構持有Immix Biopharma Inc的股份，合計持有的股份價值約為2.79M，占公司總股份的8.55% 。與2025Q2相比，機構持股有所增加，增幅為-44.11%。
哪個業務部門對Immix Biopharma Inc的收入貢獻最大？
在--，--業務部門對Immix Biopharma Inc的收入貢獻最大，創收--，占總收入的--% 。
